AnteoTech Management

Management criteria checks 2/4

AnteoTech's CEO is David Radford, appointed in Oct 2022, has a tenure of 2.08 years. total yearly compensation is A$997.56K, comprised of 46.9% salary and 53.1% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth A$134.63K. The average tenure of the management team and the board of directors is 2.1 years and 3.2 years respectively.

Key information

David Radford

Chief executive officer

AU$997.6k

Total compensation

CEO salary percentage	46.9%
CEO tenure	2.1yrs
CEO ownership	0.2%
Management average tenure	2.1yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has David Radford's remuneration changed compared to AnteoTech's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$998k	AU$468k	-AU$9m
Mar 31 2024	n/a	n/a	-AU$10m
Dec 31 2023	n/a	n/a	-AU$11m
Sep 30 2023	n/a	n/a	-AU$12m
Jun 30 2023	AU$898k	AU$338k	-AU$13m

Compensation vs Market: David's total compensation ($USD655.08K) is above average for companies of similar size in the Australian market ($USD299.41K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Radford

2.1yrs

Tenure

AU$997,558

Compensation

Mr. David John Radford, BSc (Hons), MBA, MAICD served as Chief Executive Officer of The Hydroponics Company Limited from October 19, 2017 to March 23, 2018. He serves as Managing Director, Chief Executive...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
David Radford	MD, CEO & Executive Director	2.1yrs	AU$997.56k	0.21% A$ 134.6k
Andrew Cook	CFO & Company Secretary	1.3yrs	AU$351.90k	no data
Katrina Byrne	Chief Operating Officer	2.1yrs	AU$361.18k	no data
N. Maeji	Founder & Chief Scientific Officer	no data	AU$228.47k	no data
Manuel Wieser	Chief Technology Officer	no data	no data	no data
Tsui Lian	Chief Marketing Officer	1.7yrs	no data	no data
Selahattin Guldu	Executive Vice President of Commercial Banking	6.6yrs	no data	no data
Ian Steinhardt	Head of Market Operations for Life Sciences	2.9yrs	no data	no data
Friederike Graser	Director of Strategic Growth Initiatives	no data	no data	no data

2.1yrs

Average Tenure

Experienced Management: ADO's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
David Radford	MD, CEO & Executive Director	2.1yrs	AU$997.56k	0.21% A$ 134.6k
Katherine Woodthorpe	Independent Non-Executive Director & Member of the Energy Advisory Board	3.2yrs	AU$102.88k	0.032% A$ 20.8k
Glenda McLoughlin	Chair of the Energy Advisory Board & Independent Non-Executive Director	3.2yrs	AU$105.38k	0.048% A$ 30.9k
Ewen Graham Crouch	Independent Non-Executive Chairman	2.6yrs	AU$155.58k	0.18% A$ 115.4k
Geoffrey Cumming	Member of Clinical Advisory Board & Independent Non-Executive Director	15.6yrs	AU$86.74k	1.06% A$ 683.0k
Paul Young	Member of Clinical Advisory Board	3.2yrs	no data	no data
Oliver Gross	Member of Energy Advisory Board	3.2yrs	no data	no data
Kevin Eberman	Member of Energy Advisory Board	3.2yrs	no data	no data
Dominic Dwyer	Member of Clinical Advisory Board	3.2yrs	no data	no data
Christian Page	Member of Energy Advisory Board	2.8yrs	no data	no data

3.2yrs

Average Tenure

68yo

Average Age

Experienced Board: ADO's board of directors are considered experienced (3.2 years average tenure).

AnteoTech Management

Management criteria checks 2/4

Key information

Recent management updates

AnteoTech Limited, Annual General Meeting, Nov 26, 2024

AnteoTech Limited, Annual General Meeting, May 28, 2024

AnteoTech Limited, Annual General Meeting, Nov 14, 2023

AnteoTech Limited, Annual General Meeting, Nov 14, 2023

Anteotech Limited Announces Appointment of Mr. Andrew Cook as Chief Financial Officer

AnteoTech Limited Announces Retirement of Christopher Parker from the Board of Directors

Recent updates

AnteoTech Limited, Annual General Meeting, Nov 26, 2024

New major risk - Financial position

Full year 2024 earnings released: AU$0.004 loss per share (vs AU$0.006 loss in FY 2023)

AnteoTech Limited to Report Fiscal Year 2024 Results on Aug 28, 2024

New minor risk - Share price stability

AnteoTech Limited, Annual General Meeting, May 28, 2024

AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 5.4 million.

AnteoTech Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

We're Keeping An Eye On AnteoTech's (ASX:ADO) Cash Burn Rate

AnteoTech Limited to Report First Half, 2024 Results on Feb 28, 2024

AnteoTech Limited, Annual General Meeting, Nov 14, 2023

AnteoTech Limited, Annual General Meeting, Nov 14, 2023

Full year 2023 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Anteotech Limited Announces Appointment of Mr. Andrew Cook as Chief Financial Officer

AnteoTech Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

New major risk - Share price stability

AnteoTech Limited Announces Retirement of Christopher Parker from the Board of Directors

Will AnteoTech (ASX:ADO) Spend Its Cash Wisely?

Board Member exercised options to buy AU$70k worth of stock.

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2022)

AnteoTech Limited Appoints Tsui Min Lian as Chief Marketing Officer, Effective 15 March 2023

Non-Executive Director recently sold AU$61k worth of stock

Is AnteoTech (ASX:ADO) In A Good Position To Invest In Growth?

High number of new and inexperienced directors

AnteoTech Ltd Announces Halt of European Rat Clinical Trial to Refocus Initiatives

AnteoTech Limited Appoint Executives

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.003 loss in FY 2021)

AnteoTech Limited, Annual General Meeting, Nov 17, 2022

Companies Like AnteoTech (ASX:ADO) Are In A Position To Invest In Growth

AnteoTech Limited Appoints David Radford as Managing Director, Effective from 4 October 2022

AnteoTech Limited SHS to Be Deleted from OTC Equity

Non-Executive Director recently sold AU$106k worth of stock

AnteoTech Ltd Announces Updated COVID-19 RAT Receives Regulatory Approval in Europe

Non-Executive Director recently sold AU$220k worth of stock

High number of new and inexperienced directors

AnteoTech Limited Announces Executive Changes

Companies Like AnteoTech (ASX:ADO) Are In A Position To Invest In Growth

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

AnteoTech Limited Provides Update on Its Therapeutic Goods Administration Submission

AnteoTech Limited Provides Update on Its Therapeutic Goods Administration Submission

Non-Executive Director recently sold AU$108k worth of stock

Company Secretary Duncan Cornish has left the company

High number of new and inexperienced directors

We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth

High number of new and inexperienced directors

Independent Non-Executive Director recently bought AU$59k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.002 loss in FY 2020)

Chief Financial Officer Gail Jukes has left the company

Non-Executive Director recently sold AU$112k worth of stock

AnteoTech Limited has completed a Follow-on Equity Offering in the amount of AUD 12.000001 million.

AnteoTech Limited announced that it expects to receive AUD 12.000001 million in funding

We Think AnteoTech (ASX:ADO) Can Easily Afford To Drive Business Growth

Independent Non-Executive Director has left the company

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in 1H 2020)

New 90-day high: AU$0.21

AnteoTech Customer Ellume Secures Us Contract

We're Not Very Worried About AnteoTech's (ASX:ADO) Cash Burn Rate

AnteoTech Progresses COVID-19 Test Toward Market Launch

AnteoTech Ltd Freeze Design of COVID-19 Antigen Rapid Test After Showing Saliva Proxy Sample Use Case Effectiveness

Independent Non-Executive Director exercised options to buy AU$208k worth of stock.

Full year earnings released - AU$0.002 loss per share

CEO Compensation Analysis

CEO